Article Figures & Data
Figures
- Figure 1.
Structure of the modified Michaelis-Menten pharmacokinetics/pharmacodynamics model of methotrexate (MTX) decomposition by glucarpidase. Cat: Catalyst; K12: distribution rate constant for transfer from central to peripheral; K21: distribution rate constant for transfer from peripheral to central; Kd: Degradation rate constant; Ke: elimination rate constant of glucarpidase; Km: Michaelis–Menten kinetics of methotrexate hydrolysis by glucarpidase; Kr: Renal elimination rate constant of methotrexate; V: volume of distribution of glucarpidase; VcMTX: central compartment volume of distribution of methotrexate; VpMTX: peripheral compartment volume of distribution of methotrexate; Xc: amount of central compartment of methotrexate; Xp: amount of peripheral compartment of methotrexate; α: conversion constant.
- Figure 2.
Plasma (black lines) and peripheral (red lines) methotrexate and plasma glucarpidase (green lines) log-concentrations versus time profile for therapy with 20 U/kg (A) and 50 U/kg (B) of glucarpidase using Monte–Carlo simulation.
- Figure 3.
Mean plasma methotrexate concentration (log) versus time profile at all doses of glucarpidase (A) and highlighting those at 20 and 50 U/kg (B) (mean + standard deviation).
- Figure 4.
The proportion of samples in which the plasma methotrexate concentration was less than 0.1 μmol/l (A) and less than 1.0 μmol/l (B) at 70 and 120 h after methotrexate treatment according to the dose of glucarpidase (CPG2).
Tables
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.